Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.03.235291v1?rss=1 Authors: Iketani, S., Forouhar, F., Liu, H., Hong, S. J., Lin, F.-Y., Nair, M. S., Zask, A., Huang, Y., Xing, L., Stockwell, B. R., Chavez, A., Ho, D. D. Abstract: We report the identification of three structurally diverse compounds, compound 4, GC376, and MAC-5576, as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors. Copy rights belong to original authors. Visit the link for more info